Literature DB >> 35273475

Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia.

Norah Alharbi1, Rawan Matar2, Edward Cupler3, Hindi Al-Hindi4, Hatem Murad5, Iftteah Alhomud5, Dorota Monies6, Ali Alshehri5, Mossaed Alyahya5, Brian Meyer6, Saeed Bohlega5.   

Abstract

Background: To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy.
Methods: A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYSF) gene was done in a tertiary care referral hospital in Saudi Arabia. Clinical, Neurophysiological, Radiological, Pathological, and Genetic findings in subjects with dysferlin mutation were the primary outcome variables. Statistical analysis was done by Epi-info.
Results: 33 out of 112 families (29.46%) registered in the LGMD cohort had Dysferlinopathy. 53 subjects (28 males, 52.83%) from 33 families were followed up for various periods ranging from 1 to 28 years. The mean age of onset was 17.79 ± 3.48 years (Range 10 to 25 years). Miyoshi Myopathy phenotype was observed in 50.94% (27 out of 53), LGMDR2 phenotype in 30.19% (16 out of 53), and proximodistal phenotype in 15.09% (8 out of 53) of the subjects. Loss of ambulation was observed in 39.62% (21 out of 53 subjects). Electrophysiological, Radiological, and histopathological changes were compatible with the diagnosis. Mean serum Creatinine Kinase was 6,464.45 ± 4,149.24 with a range from 302 to 21,483 IU/L. In addition, 13 dysferlin mutations were identified two of them were compound heterozygous. One founder mutation was observed c.164_165insA in 19 unrelated families.
Conclusion: The prevalence of Dysferlinopathy was 29.46% in the native Saudi LGMD cohort. It is the most prevalent subtype seconded by calpainopathy. The clinical course varied among the study subjects and was consistent with those reported from different ethnic groups. One founder mutation was identified. Initial screening of the founder mutations in new families is highly recommended.
Copyright © 2022 Alharbi, Matar, Cupler, Al-Hindi, Murad, Alhomud, Monies, Alshehri, Alyahya, Meyer and Bohlega.

Entities:  

Keywords:  DYSF gene; LGMD2B; Miyoshi myopathy; Saudi Arabia; dysferlin; dysferlinopathy; limb-girdle muscular dystrophies (LGMD); neurophysiological profile

Year:  2022        PMID: 35273475      PMCID: PMC8902167          DOI: 10.3389/fnins.2022.815556

Source DB:  PubMed          Journal:  Front Neurosci        ISSN: 1662-453X            Impact factor:   4.677


  67 in total

1.  229th ENMC international workshop: Limb girdle muscular dystrophies - Nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017.

Authors:  Volker Straub; Alexander Murphy; Bjarne Udd
Journal:  Neuromuscul Disord       Date:  2018-05-24       Impact factor: 4.296

2.  Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies.

Authors:  Karine Nguyen; Guillaume Bassez; Rafaëlle Bernard; Martin Krahn; Véronique Labelle; Dominique Figarella-Branger; Jean Pouget; El Hadi Hammouda; Christophe Béroud; Andoni Urtizberea; Bruno Eymard; France Leturcq; Nicolas Lévy
Journal:  Hum Mutat       Date:  2005-08       Impact factor: 4.878

3.  Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies.

Authors:  C Paradas; J Llauger; J Diaz-Manera; R Rojas-García; N De Luna; C Iturriaga; C Márquez; M Usón; K Hankiewicz; E Gallardo; I Illa
Journal:  Neurology       Date:  2010-06-23       Impact factor: 9.910

4.  Rapid screening for Japanese dysferlinopathy by fluorescent primer extension.

Authors:  Saori Hayashi; Yutaka Ohsawa; Toshiaki Takahashi; Naoki Suzuki; Tadashi Okada; Mitsue Rikimaru; Tatsufumi Murakami; Masashi Aoki; Yoshihide Sunada
Journal:  Intern Med       Date:  2010-12-15       Impact factor: 1.271

5.  Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC Consortium on Limb-Girdle Dystrophies.

Authors:  K M Bushby
Journal:  Neuromuscul Disord       Date:  1995-01       Impact factor: 4.296

Review 6.  The 10 autosomal recessive limb-girdle muscular dystrophies.

Authors:  Mayana Zatz; Flavia de Paula; Alessandra Starling; Mariz Vainzof
Journal:  Neuromuscul Disord       Date:  2003-09       Impact factor: 4.296

Review 7.  Dysferlinopathies.

Authors:  J Andoni Urtizberea; Guillaume Bassez; France Leturcq; Karine Nguyen; Martin Krahn; Nicolas Levy
Journal:  Neurol India       Date:  2008 Jul-Sep       Impact factor: 2.117

8.  Pattern of skeletal muscle involvement in primary dysferlinopathies: a whole-body 3.0-T magnetic resonance imaging study.

Authors:  K Kesper; C Kornblum; J Reimann; G Lutterbey; R Schröder; M P Wattjes
Journal:  Acta Neurol Scand       Date:  2008-12-22       Impact factor: 3.209

9.  Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials.

Authors:  Jordi Diaz-Manera; Roberto Fernandez-Torron; Jaume LLauger; Meredith K James; Anna Mayhew; Fiona E Smith; Ursula R Moore; Andrew M Blamire; Pierre G Carlier; Laura Rufibach; Plavi Mittal; Michelle Eagle; Marni Jacobs; Tim Hodgson; Dorothy Wallace; Louise Ward; Mark Smith; Roberto Stramare; Alessandro Rampado; Noriko Sato; Takeshi Tamaru; Bruce Harwick; Susana Rico Gala; Suna Turk; Eva M Coppenrath; Glenn Foster; David Bendahan; Yann Le Fur; Stanley T Fricke; Hansel Otero; Sheryl L Foster; Anthony Peduto; Anne Marie Sawyer; Heather Hilsden; Hanns Lochmuller; Ulrike Grieben; Simone Spuler; Carolina Tesi Rocha; John W Day; Kristi J Jones; Diana X Bharucha-Goebel; Emmanuelle Salort-Campana; Matthew Harms; Alan Pestronk; Sabine Krause; Olivia Schreiber-Katz; Maggie C Walter; Carmen Paradas; Jean-Yves Hogrel; Tanya Stojkovic; Shin'ichi Takeda; Madoka Mori-Yoshimura; Elena Bravver; Susan Sparks; Luca Bello; Claudio Semplicini; Elena Pegoraro; Jerry R Mendell; Kate Bushby; Volker Straub
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-05-07       Impact factor: 10.154

10.  Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population.

Authors:  Fiona L M Norwood; Chris Harling; Patrick F Chinnery; Michelle Eagle; Kate Bushby; Volker Straub
Journal:  Brain       Date:  2009-09-18       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.